Thus, in perfect agreement with the recent ADA-EASD consensus report [6], we also encourage the adoption of GLP-1RA plus SGLT2i combination therapy in T2DM patients with established ASCVD (coronary artery disease, cerebrovascular disease, or peripheral arterial disease) or multiple risk factors for ASCVD (i.e., age 55 years, obesity, dyslipidemia, hypertension, current tobacco use, left ventricular hypertrophy, and/or proteinuria) whose HbA1c remains suboptimal despite initial treatment with only one of these agents
Renin-angiotensin system (RAS) inhibition has been the mainstay of renal protective therapy for a quarter century, Dr
Frequently Asked Questions Does Semaglutide affect sleep
these results will be presented in a separate manuscript
This is a normal physiological response that occurs in most people during extended weight loss efforts